Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Clinician Update

How to Interpret Elevated Cardiac Troponin Levels

Vinay S. Mahajan, Petr Jarolim
Download PDF
https://doi.org/10.1161/CIRCULATIONAHA.111.023697
Circulation. 2011;124:2350-2354
Originally published November 21, 2011
Vinay S. Mahajan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petr Jarolim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • What Is a High-Sensitivity Troponin Test?
    • What Is a Positive Troponin Result? The 99th Percentile Rule
    • The Specificity of a Troponin Test for ACS
    • The Need for Serial Troponin Testing
    • Conclusions
    • Disclosures
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Cardiac troponin (cTn) testing is an essential component of the diagnostic workup and management of acute coronary syndromes (ACS). Although over the past 15 years the diagnostic performance of the previous gold-standard assay, creatine kinase-MB, has not changed appreciably, the ever-increasing sensitivity of cTn assays has had a dramatic impact on the use of cTn testing to diagnose ACS.1 Here, we present 3 recent clinical cases from the emergency department with acute chest discomfort that exemplify the challenges introduced by high-sensitivity cTn assays: a 48-year-old man who presented to the emergency department with chest discomfort lasting 2 hours and a 3-day history of flu-like symptoms whose ECG showed diffuse ST-segment changes, a 60-year-old woman with a medical history of heart failure who presented to the emergency department with chest pain lasting 1.5 hours whose ECG was nondiagnostic, and a 54-year-old man with a medical history of diabetes mellitus who presented with chest discomfort lasting 1 hour whose ECG was normal.

Cardiac troponin I (cTnI) testing (TnI-Ultra assay on the ADVIA Centaur XP immunoanalyzer, both Siemens Healthcare Diagnostics) was ordered on all 3 patients. The laboratory results were reported as positive in all 3 cases, with the reported values being 0.05, 0.06, and 0.06 ng/mL, respectively, all just above the diagnostic limit of 0.04 ng/mL.

Assays for cTn, namely cTnI and cardiac troponin T (cTnT), are the preferred diagnostic tests for ACS, in particular non–ST-segment–elevation myocardial infarction, because of the tissue-specific expression of cTnI and cTnT in the myocardium. The results of cTn testing often guide the decision for coronary intervention. However, although the increasing sensitivity of cTn assays lowers the number of potentially missed ACS diagnoses, it presents a diagnostic challenge because the gains in diagnostic sensitivity have inevitably come with a decrease in specificity. For instance, the replacement of the cTn assay (Siemens Healthcare Diagnostics) by the more sensitive TnI-UItra assay in the Brigham and Women's Hospital Clinical Laboratories in early 2007 resulted in a doubling of positive cTn results in samples collected in the emergency department2 even though there was no change in the frequency of final diagnoses of ACS.

What Is a High-Sensitivity Troponin Test?

Rapid advances in immunoassay technologies and the international adoption of traceable troponin calibration standards have allowed manufacturers to develop and calibrate troponin assays with unprecedented analytic sensitivity and precision. Thus, a contemporary cTnI assay such as TnI-Ultra detects plasma cTn levels as low as 0.006 ng/mL with an assay range that spans 4 orders of magnitude (0.006–50 ng/mL). Similarly, the limit of detection of a contemporary cTnT assay (Elecsys TnT-hs, Roche Diagnostics; approved for clinical use in Europe but not yet in the United States) is as low as 0.005 ng/mL.3 Although cTnI and cTnT concentrations correlate to some extent, the numeric values can be quite different in a given patient, with cTnT readings generally being lower. Between 1995 and 2007, the limit of detection fell from 0.5 ng/mL for some cTn assays to 0.006 ng/mL for TnI-Ultra, an ≈100-fold improvement in analytic sensitivity (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Evolution of the cardiac troponin (cTn) assays and their diagnostic cutoffs. A hypothetical case of acute coronary syndrome is depicted with the earliest times of potential diagnosis corresponding to the diagnostic cutoffs of more sensitive cTn assays. The years correspond to the availability of the respective assays in the US market.

Remarkably, the use of contemporary high-sensitivity cTn assays makes it possible to detect low levels of cTn even in plasma from healthy subjects. Indeed, high-sensitivity cTn assays are designated as such on the basis of their ability to detect cTns even in healthy individuals. The latest generation of high-sensitivity cTn assays can detect cTn in >95% of a reference population.4 The ability to detect cTns in healthy individuals made it imperative to define a clinical decision limit for cTn concentration, ie, a “positive” cTn result.

What Is a Positive Troponin Result? The 99th Percentile Rule

The National Academy of Clinical Biochemistry issued a guideline in 2007 that stated that “in the presence of a clinical history suggestive of ACS, the following is considered indicative of myocardial necrosis consistent with myocardial infarction: maximal concentration of cTn exceeding the 99th percentile of values (with optimal precision defined by total c.v. [coefficient of variation] <10%) for a reference control group on at least one occasion during the first 24 hours after the clinical event.”5 This guideline provides the framework for determining the decision limit or a “positive” troponin result.

Based on the 99th percentile rule, troponin decision limits of several high-sensitivity cTn assays can be set as low as 0.01 ng/mL.6 This makes it possible to identify patients with ACS earlier, enabling earlier coronary intervention (Figure 2). However, while improving clinical sensitivity for the diagnosis of myocardial infarction, the increased analytic sensitivity has come at the cost of reduced specificity, thus presenting an additional diagnostic challenge for clinicians.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Cardiac troponin I (cTnI) levels in a healthy reference population and in an acute coronary syndrome (ACS) population. Top, Frequency histograms of real TnI levels (blue filled) in healthy reference controls are shown, along with the distribution of the same TnI levels as measured with a less precise cTnI (green) and the more precise TnI-Ultra (blue) assay for comparison. In practice, the values below the assay detection threshold (dashed portions of the histogram plots) cannot be distinguished from one another. Note how the 99th percentile decision limits decrease with increased assay precision. Bottom, Hypothetical frequency histograms of cTnI concentrations in individuals with ACS <2, 2 to 3, or 3 to 4 hours after the onset of symptoms. The decision limits (dashed vertical lines) for the contemporary high-sensitivity cTnI assays are based on the 99th percentile in a healthy reference population. Note the impact of decreased diagnostic cutoffs of the newer cTnI assays on the fraction of acute myocardial infarctions diagnosed at earlier time intervals. (All frequency histograms in this figure are hypothetical and for illustrative purposes only.)

The Specificity of a Troponin Test for ACS

The use of the 99th percentile cutoff for cTn positivity does not imply that 1% of the population suffers from myocardial damage. Rather, this cutoff is useful only when applied to patients with a high pretest probability of ACS. The clinician must interpret cTn results in the context of clinical history, ECG findings, and possibly cardiac imaging to establish the correct diagnosis. A positive troponin in the setting of a low pretest probability for ACS may be suggestive but clearly is not indicative of a coronary event. Unfortunately, the pressure to avoid malpractice litigation forces many clinicians to order comprehensive panels of laboratory tests, including cTn, for patients with a very low pretest probability of ACS, which adversely affects the positive predictive value of cTn assays for diagnosing myocardial infarction.

Traditional wisdom, before the advent of high-sensitivity cTn assays, held that troponins do not appear in the circulation of individuals with a healthy myocardium. These levels used to be considered indicative of myocardial necrosis. However, with high-sensitivity troponin assays, circulating cTnT or cTnI can be found in the plasma as a result of transient ischemic or inflammatory myocardial injury. Thus, elevated cTn may be detected in conditions other than ACS (the Table), including heart failure, cardiomyopathies, myocarditis, renal failure, tachyarrhythmias, and pulmonary embolism, and even after strenuous exercise in healthy individuals.8

View this table:
  • View inline
  • View popup
Table.

Causes of Elevated Plasma Cardiac Troponin Other Than Acute Coronary Syndromes

The Need for Serial Troponin Testing

In addition to the absolute level of cTn in plasma or serum above the decision limit, a critical component of the diagnosis of ACS is cTn kinetics. This was reiterated in the current universal definition of myocardial infarction adopted in 2007.5 Although absolute cTn elevations are seen in multiple chronic cardiac and noncardiac conditions, a rise or fall in serial cTn levels strongly supports an acutely evolving cardiac injury such as, most commonly, acute myocardial infarction.

Serial cTn testing helped establish final diagnoses in our 3 patients. Patient 1 (Figure 3, top) had a steady but relatively slow increase in cTnI with a peak value of 0.9 ng/mL. The findings of acute dilated cardiomyopathy and global ventricular dysfunction on echocardiography were consistent with a diagnosis of acute myocarditis.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Troponin kinetics in the index cases. Plasma cardiac troponin I (cTnI) values in the 3 index cases. The cutoff for the TnI assay (0.04 ng/mL) is indicated with a dashed horizontal line. See the text for detailed description.

Patient 2 (Figure 3, middle) had modest cTn elevations fluctuating just above the decision limit in the 0.05 to 0.09 ng/mL range. She was diagnosed with acutely decompensated heart failure. Additional TnI testing did not provide evidence of ACS.

TnI levels in patient 3 (Figure 3, bottom) rose to a peak of 53 ng/mL within 24 hours. He was diagnosed with non–ST-segment–elevation myocardial infarction when the second cTn result of 6.3 ng/mL was obtained after 6 hours. The rapid, steep increase from the initial barely positive value of 0.06 ng/mL to the 6-hour value of 6.3 ng/mL illustrates that more frequent testing during the first several hours may be sufficient to detect a diagnostic rise in cTn levels that is eventually destined to increase by a few orders of magnitude such as the peak of 53 ng/mL in this patient.

Fortunately, simultaneous improvements in contemporary assay sensitivity and precision allow 2 cTn values with a difference as small as a few hundredths of 1 ng/mL to be distinguished reliably. This has significant implications for serial cTn testing.

Previously, clinicians often had to wait an average of 6 hours with the lower-sensitivity, lower-precision cTn assays to see a conclusive increase in plasma cTn levels after the first troponin measurement, but today's high-sensitivity cTn tests that are separated by a mere 2 to 3 hours can be highly informative. Given the urgent need for early diagnosis of ACS and appropriate emergency intervention, as well as the ease of performing this relatively inexpensive assay, clinicians do not need to wait 6 to 8 hours before ordering a second troponin test to rule in ACS. We recommend collecting a second specimen for cTn testing within 2 to 3 hours from the collection of the blood sample at presentation to help confirm the diagnosis of MI.

Conclusions

Commenting on the ever-increasing sensitivity and decreasing specificity of cTn assays, Robert Jesse quipped, “When troponin was a lousy assay it was a great test, but now that it's becoming a great assay, it's getting to be a lousy test.”9 However, frequent monitoring of cTn kinetics, along with careful attention to the noncoronary causes of cTn elevations, will keep the high-sensitivity cTn assays in the class where they rightfully belong—among the greatest, most useful assays in clinical chemistry laboratories.

Disclosures

Dr Jarolim has research grants from Roche Diagnostics, Siemens Healthcare Diagnostics, Ortho Clinical Diagnostics, Beckman Coulter, Inc, and Amgen, as well as honoraria from Ortho Clinical Diagnostics and Roche Diagnostics. Dr Mahajan reports no conflicts.

  • © 2011 American Heart Association, Inc.

References

  1. 1.↵
    1. Melanson SEF,
    2. Morrow DA,
    3. Jarolim P
    . Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol. 2007;128:282–286.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Melanson SEF,
    2. Conrad MJ,
    3. Mosammaparast N,
    4. Jarolim P
    . Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin Chim Acta. 2008;395:57–61.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Saenger AK,
    2. Beyrau R,
    3. Braun S,
    4. Cooray R,
    5. Dolci A,
    6. Freidank H,
    7. Giannitsis E,
    8. Gustafson S,
    9. Handy B,
    10. Katus H,
    11. Melanson SE,
    12. Panteghini M,
    13. Venge P,
    14. Zorn M,
    15. Jarolim P,
    16. Bruton D,
    17. Jarausch J,
    18. Jaffe AS
    . Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta. 2011;412:748–754.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Apple FS
    . A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2009;55:1303–1306.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Thygesen K,
    2. Alpert JS,
    3. White HD,
    4. Jaffe AS,
    5. Apple FS,
    6. Galvani M,
    7. Katus HA,
    8. Newby LK,
    9. Ravkilde J,
    10. Chaitman B,
    11. Clemmensen PM,
    12. Dellborg M,
    13. Hod H,
    14. Porela P,
    15. Underwood R,
    16. Bax JJ,
    17. Beller GA,
    18. Bonow R,
    19. Van der Wall EE,
    20. Bassand JP,
    21. Wijns W,
    22. Ferguson TB,
    23. Steg PG,
    24. Uretsky BF,
    25. Williams DO,
    26. Armstrong PW,
    27. Antman EM,
    28. Fox KA,
    29. Hamm CW,
    30. Ohman EM,
    31. Simoons ML,
    32. Poole-Wilson PA,
    33. Gurfinkel EP,
    34. Lopez-Sendon JL,
    35. Pais P,
    36. Mendis S,
    37. Zhu JR,
    38. Wallentin LC,
    39. Fernández-Avilés F,
    40. Fox KM,
    41. Parkhomenko AN,
    42. Priori SG,
    43. Tendera M,
    44. Voipio-Pulkki LM,
    45. Vahanian A,
    46. Camm AJ,
    47. De Caterina R,
    48. Dean V,
    49. Dickstein K,
    50. Filippatos G,
    51. Funck-Brentano C,
    52. Hellemans I,
    53. Kristensen SD,
    54. McGregor K,
    55. Sechtem U,
    56. Silber S,
    57. Tendera M,
    58. Widimsky P,
    59. Zamorano JL,
    60. Morais J,
    61. Brener S,
    62. Harrington R,
    63. Morrow D,
    64. Lim M,
    65. Martinez-Rios MA,
    66. Steinhubl S,
    67. Levine GN,
    68. Gibler WB,
    69. Goff D,
    70. Tubaro M,
    71. Dudek D,
    72. Al-Attar N
    . Universal definition of myocardial infarction. Circulation. 2007;116:2634–2653.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Apple FS,
    2. Parvin CA,
    3. Buechler KF,
    4. Christenson RH,
    5. Wu AHB,
    6. Jaffe AS
    . Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem. 2005;51:2198–2200.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Jaffe AS,
    2. Babuin L,
    3. Apple FS
    . Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1–11.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mingels AMA,
    2. Jacobs LHJ,
    3. Kleijnen VW,
    4. Laufer EM,
    5. Winkens B,
    6. Hofstra L,
    7. Wodzig WK,
    8. van Dieijen-Visser MP
    . Cardiac troponin T elevations, using highly sensitive assay, in recreational running depend on running distance. Clin Res Cardiol. 2010;99:385–391.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Jesse RL
    . On the relative value of an assay versus that of a test: a history of troponin for the diagnosis of myocardial infarction. J Am Coll Cardiol. 2010;55:2125–2128.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
November 22, 2011, Volume 124, Issue 21
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • What Is a High-Sensitivity Troponin Test?
    • What Is a Positive Troponin Result? The 99th Percentile Rule
    • The Specificity of a Troponin Test for ACS
    • The Need for Serial Troponin Testing
    • Conclusions
    • Disclosures
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    How to Interpret Elevated Cardiac Troponin Levels
    Vinay S. Mahajan and Petr Jarolim
    Circulation. 2011;124:2350-2354, originally published November 21, 2011
    https://doi.org/10.1161/CIRCULATIONAHA.111.023697

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    How to Interpret Elevated Cardiac Troponin Levels
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    How to Interpret Elevated Cardiac Troponin Levels
    Vinay S. Mahajan and Petr Jarolim
    Circulation. 2011;124:2350-2354, originally published November 21, 2011
    https://doi.org/10.1161/CIRCULATIONAHA.111.023697
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Imaging and Diagnostic Testing
    • Diagnostic Testing
  • Basic, Translational, and Clinical Research
    • Metabolism
  • Heart Failure and Cardiac Disease
    • Myocardial Infarction
  • Vascular Disease
    • Acute Coronary Syndromes
  • Cardiology
    • Etiology
      • Acute myocardial infarction
      • Acute coronary syndromes

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured